SEC Form 4 · accession 0001104659-19-005904
Ra Pharmaceuticals, Inc. · RARX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas A Treco
Officer — President and CEO · Director
Period of report
Feb 1, 2019
Accepted (ET)
Feb 5, 2019 · 7:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001481512
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCKF1 | Feb 1, 2019 | M | 20,834 | — | A | 225,126 | D | |
| COMMON STOCK | Feb 1, 2019 | F | 6,327 | $21.00 | D | 218,799 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF2 | $21.00 | Feb 1, 2019 | A | 311,000 | A | — | Feb 1, 2029 | Common Stock | 311,000 | 311,000 | D |
| Restricted Stock UnitsF1,F3,F4 | — | Feb 1, 2019 | M | 20,834 | D | — | — | Common Stock | 20,834 | 41,666 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- F2These stock options vest in 48 equal monthly installments on each monthly anniversary following February 1, 2019, the grant date.
- F3On February 1, 2018, the reporting person was granted 62,500 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
- F4Not applicable.